Get started
Author

Heather Wray

Observed names: H Wray, H. Wray
ORCID: 0000-0002-2969-3192
Observed ORCID: 0000-0002-2969-3192
OpenAlex ID: A5113563008
A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis
2015 · Anthony De Soyza, Ian Pavord, et al. · European Respiratory Journal · 113
The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD
2015 · A.M. Kirsten, K. Förster, et al. · Pulmonary Pharmacology & Therapeutics · 91
Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: A randomised controlled trial
2012 · Ronald Dahl, Ingrid Titlestad, et al. · Pulmonary Pharmacology & Therapeutics · 84
Combined scintigraphic and pharmacokinetic investigation of enteric‐coated mesalazine micropellets in healthy subjects
2003 · I. R. Wilding, C. Behrens, et al. · Alimentary Pharmacology & Therapeutics · 42
Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: A randomised controlled 6-week trial
2011 · Helgo Magnussen, Henrik Watz, et al. · Pulmonary Pharmacology & Therapeutics · 40
Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers
2018 · Marie Cullberg, Cecilia Arfvidsson, et al. · Drugs in R&D · 26
PDF
Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers
2010 · Armel Stockis, Maria Laura Sargentini-Maier, et al. · Clinical Therapeutics · 23
Pharmacoscintigraphic Assessment of the Regional Drug Absorption of the Dual Angiotensin-Converting Enzyme/Neutral Endopeptidase Inhibitor, M100240, in Healthy Volunteers
2003 · Nancy E. Martin, Kathryn R. Collison, et al. · The Journal of Clinical Pharmacology · 23
A scintigraphic study to investigate the potential for altered gut distribution of loperamide from a loperamide–simethicone formulation in man
2001 · A.L Connor, H Wray, et al. · European Journal of Pharmaceutical Sciences · 16
The assessment of human regional drug absorption of free acid and sodium salt forms of Acipimox, in healthy volunteers, to direct modified release formulation strategy
2009 · Rajeev Menon, Eugenio Cefali, et al. · Biopharmaceutics & Drug Disposition · 13
Effectiveness of a risk-minimization activity involving physician education on metabolic monitoring of patients receiving quetiapine
2015 · Robert S. Brody, Charles L. Liss, et al. · International Clinical Psychopharmacology · 12
Comparative Assessment of a New Breath-Actuated Inhaler in Patients with Reversible Airways Obstruction
2009 · J.C. Waterhouse, J.L Simmons, et al. · Respiration · 11
In Vivo Disintegration Profiles of Encapsulated and Nonencapsulated Sumatriptan: Gamma Scintigraphy in Healthy Volunteers
2004 · Ian R. Wilding, Darren Clark, et al. · The Journal of Clinical Pharmacology · 8
Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis
2013 · Ian Pavord, Anthony De Soyza, et al. · European Respiratory Journal · 7
A Pharmacokinetic and Scintigraphic Comparison of MMX™ mesalamine and Delayed-Release mesalamine
2008 · Heather Wray, Raymond Joseph, et al. · The American Journal of Gastroenterology · 7
A Post-Authorization Safety Study of Quetiapine as Antidepressant Treatment in Sweden: Nested Case–Control Analyses of Select Outcomes
2019 · Johan Reutfors, Philip Brenner, et al. · Drug Safety · 6
PDF
Pharmacoscintigraphic Comparison of HMR 1031, a VLA-4 Antagonist, in Healthy Volunteers Following Delivery Via a Nebulizer and a Dry Powder Inhaler
2004 · Shashank Rohatagi, Sunny Chapel, et al. · American Journal of Therapeutics · 6
An open‐label randomized study of the relative absorption of gastro‐resistant risedronate taken fasted or with food versus immediate‐release risedronate
2022 · Diane Kleinermans, Andrew Joyson, et al. · Pharmacology Research & Perspectives · 3
PDF
Safety and tolerability of single doses of AZD5069 in healthy volunteers
2011 · Heather Wray, Andrew Sparrow · European Respiratory Journal · 2
Results from a drug utilization study of extended release quetiapine fumarate prescribed by psychiatrists as treatment for major depressive disorder in selected countries in the European Union
2017 · Robert S. Brody, Charles L. Liss, et al. · International Clinical Psychopharmacology · 1
Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of AZD5069, an oral CXCR2 antagonist
2014 · Marie Cullberg, Heather Wray, et al. · European Respiratory Journal · 1
The absorption, distribution, metabolism and excretion (ADME) of single oral doses of AZD5069, a novel CXCR2 antagonist, in healthy male volunteers
2012 · Tim Mant, Heather Wray, et al. · European Respiratory Journal · 1
Combined pharmacokinetic and scintigraphic analyses for the comparison of 5-ASA release profiles from MMX™ mesalamine and another delayed-release mesalamine formulation
2008 · H Wray, R Joseph, et al. · Inflammatory Bowel Diseases · 1
Efficacy of Zolmitriptan Nasal Spray for the Treatment of Acute Migraine in Adolescents: Subgroup analysis by Age (S52.005)
2017 · Paul Winner, Robert Rubens, et al. · Neurology
Physician Online Survey
2016 · Robert S. Brody, Charles L. Liss, et al. · PsycTESTS Dataset
Works count: 25
Citation count: 537
H-index: 11
I10-index: 12
Year
Topic
Type